The High Content Screening Market Is Estimated To Witness High Growth Owing To Advancements In Cell Imaging Technologies
The high content screening market is estimated to be valued at US$ 1,847.2 Mn in 2023 and is expected to exhibit a CAGR of 5.8% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
High content screening is a cell imaging based methodology that is used to observe, analyze and quantitatively assess perturbations in cell morphology and function. It allows multi-parametric measurements of biological processes through multiparametric cell image analysis. High content screening finds wide applications in disease research, drug discovery and life science research.
Market Dynamics:
One of the key drivers propelling the growth of the high content screening market is the advancements in cell imaging technologies. Manufacturers are increasingly focusing on developing advanced cell imaging instruments with improved resolution, speed and throughput. For instance, in 2021, Olympus Corporation launched IXplore Spin SR optical scanning microscope offering high resolution and throughput for live cell applications. Furthermore, rising R&D investments by biotechnology and pharmaceutical companies in drug discovery is also fueling the demand for high content screening systems. Additionally, increasing prevalence of chronic diseases and growing geriatric population globally is generating demand for new drugs, thereby driving adoption of high content screening technologies in drug development processes.
SWOT Analysis
Strength: High content screening allows analysis of large number of compounds simultaneously in a miniaturized format, reducing time and cost of drug discovery. It provides quantitative image-based readout of multiple readouts like cell morphology, proliferation and cytotoxicity. High content screening systems integrate microscope, robotics, fluidics and advanced software for automated acquisition and analysis of large amounts of digitized image data.
Weakness: High content screening requires specialized equipment like high-throughput microscopes, incubators and expensive reagents and consumables which increases initial investment cost. Complex image analysis and lack of standards for data analysis are other limitations.
Opportunity: Increasing R&D investment in pharmaceutical and biotechnology companies and growing drug discovery activities provide significant growth opportunities. Rising demand for personalized medicine and companion diagnostics also present opportunities for high content screening market.
Threats: Presence of cheaper alternatives like flow cytometry, ELISA and western blotting restrict the market growth. Lack of skilled professionals for operatating complex imaging platforms and analyzing large image datasets pose challenges.
Key Takeaways:
The global high content screening market is expected to witness high growth, exhibiting CAGR of 5.8% over the forecast period, due to increasing drug discovery activities and growing focus on development of personalized medicine. Rising incidence of diseases like cancer and neurodegenerative disorders is further driving the demand for high content screening systems.
Regional analysis: North America dominated the high content screening market accounting for over 35% share in 2023 due to presence of key players and availability of funding for research. However, Asia Pacific is expected to grow at fastest pace due to increasing government support for research activities, rising biotech industry and improving diagnostic infrastructure in countries like China and India.
Key players analysis: Key players operating in the high content screening market are Becton, Dickinson and Company, Thermo Fisher Scientific Inc., GE HealthCare, Olympus Corporation, PerkinElmer Inc., Merck Millipore Corporation, Danaher, Yokogawa Electric Corporation, Sysmex Corporation, and Thorlabs, Inc. These players are focusing on new product launches and mergers & acquisitions to strengthen their market presence
